Equities analysts forecast that Clearside Biomedical Inc (NASDAQ:CLSD) will announce sales of $50,000.00 for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Clearside Biomedical’s earnings. The company is expected to report its next earnings results on Thursday, November 14th.
On average, analysts expect that Clearside Biomedical will report full year sales of $150,000.00 for the current financial year, with estimates ranging from $90,000.00 to $180,000.00. For the next year, analysts expect that the firm will post sales of $7.72 million, with estimates ranging from $500,000.00 to $20.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Clearside Biomedical.
Clearside Biomedical (NASDAQ:CLSD) last posted its earnings results on Wednesday, August 7th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.22. The firm had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.05 million.
CLSD has been the subject of several research reports. Wedbush reiterated a “buy” rating and issued a $4.00 target price on shares of Clearside Biomedical in a research report on Tuesday, August 6th. Laidlaw downgraded Clearside Biomedical from a “buy” rating to a “hold” rating in a research report on Tuesday, August 13th. ValuEngine upgraded Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research upgraded Clearside Biomedical from a “hold” rating to a “strong-buy” rating and set a $1.50 target price for the company in a research report on Monday, August 12th. Finally, Needham & Company LLC downgraded Clearside Biomedical from a “buy” rating to a “hold” rating in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. Clearside Biomedical currently has a consensus rating of “Hold” and a consensus target price of $3.64.
Clearside Biomedical stock opened at $0.61 on Monday. The company has a current ratio of 3.47, a quick ratio of 3.47 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $23.03 million, a PE ratio of -0.22 and a beta of -0.88. Clearside Biomedical has a 12 month low of $0.56 and a 12 month high of $7.07. The stock has a 50-day moving average price of $1.07 and a two-hundred day moving average price of $1.21.
Several hedge funds have recently modified their holdings of the company. Geode Capital Management LLC increased its stake in shares of Clearside Biomedical by 4.9% in the fourth quarter. Geode Capital Management LLC now owns 303,512 shares of the company’s stock valued at $324,000 after buying an additional 14,181 shares during the period. SG Americas Securities LLC increased its stake in shares of Clearside Biomedical by 63.4% in the first quarter. SG Americas Securities LLC now owns 57,234 shares of the company’s stock valued at $79,000 after buying an additional 22,213 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Clearside Biomedical by 32.8% in the fourth quarter. Bank of New York Mellon Corp now owns 111,970 shares of the company’s stock valued at $120,000 after buying an additional 27,652 shares during the period. Parallel Advisors LLC acquired a new stake in shares of Clearside Biomedical in the first quarter valued at about $87,000. Finally, A.R.T. Advisors LLC acquired a new stake in shares of Clearside Biomedical in the second quarter valued at about $95,000. 11.56% of the stock is owned by institutional investors.
About Clearside Biomedical
Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion.
Featured Story: What is Call Option Volume?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.